Phase 2 N=50 Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
Idiopathic Pulmonary Fibrosis
Primary: Drug-related Adverse Events — 1; 0; 0; 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Stem Cell Transplantation for Patients With Cancers of the Blood
CML (Chronic Myelogenous Leukemia) · CLL (Chronic Lymphocytic Leukemia) · AML (Acute Myelogenous Leukemia)
Primary: To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling…
Phase 2 N=45 Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Adenomatous Polyp · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Change in ACF pERK Levels
Phase 2 N=64 Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Number of Patients Achieving 6-month Progression-free Survival (6mPFS) — 1; 2 participants
Phase 2 N=432 Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Primary: Rate of Decline in FVC — -0.190; -0.174; -0.210; -0.162 Liters/year — p=0.8530
Phase 2 N=18 Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Cutaneous Leiomyomas · Hereditary Leiomyomatosis and Renal Cell Cancer
Primary: Change in Worst Lesional Pain in the Past Week Based on Brief Pain Inventory — -2.50; -1.26 units on a scale
Phase 2 N=78 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months
Phase 2 N=57 Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Response Rate — 0; 5 percentage of responding patients
Phase 2 N=67 Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
Neoplasms, Head and Neck
Primary: Number of Participants (Par.) With Complete Response (CR), as Assessed by Independent Radiological Review — 12; 18 Participants — p=0.3658
Phase 2 N=34 A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
Cancer · Pain
Primary: Time-weighted SPID30 — 59.9; 42.6 units on a scale — p=<0.001
Phase 2 N=16 Treatment of Liver Metastases With Electrochemotherapy
Liver Metastases
Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events
Phase 2 N=33 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Breast Cancer · Hypercalcemia of Malignancy · Colon Cancer
Primary: Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab — 63.6 percentage of participants
Phase 2 N=90 Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting
Pain
Primary: Pain Severity — 39; 43; 42 mm
Phase 2 N=306 A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Colorectal Cancer
Primary: Percentage of Participants With Disease Progression or Death — 86.14; 90.20; 88.35 percentage of participants
Phase 2 N=90 A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
Intermittent Explosive Disorder
Primary: Overt Aggression Scale-Modified for Outpatient Use (OAS-M) — 7.86; 15.73; 8.88 units on a scale — p=0.622